Introduction: Programmed death ligand 1 (PD-L1) expression determined by immunohistochemistry (IHC) may serve as a predictive biomarker for anti-PD-1/PD-L1 therapies; however, little is known about intertumoral heterogeneity of PD-L1 expression determined by IHC in lung adenocarcinomas (ADCs), and there have been conflicting results on the prognostic role of PD-L1 expression in ADCs.
Introduction
The discovery of oncogenic driver mutations and development of the corresponding targeted agents in lung cancer, in particular lung adenocarcinoma (ADC), have dramatically shifted the paradigm for lung cancer treatment. 1 Despite the impressive activity of these agents, however, resistance almost invariably develops, and a significant proportion of patients with ADC do not have genetic alterations amenable to targeted therapies. 2, 3 Now, new therapeutic approaches, in particular immunotherapies with programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade, are being vigorously investigated in lung cancer, including ADC. PD-1 is expressed on tumor antigenspecific T cells by means of signaling through the T-cell receptor when they recognize their cognate antigen expressed by cancer cells. The signal also leads to production of interferons that in turn induce the expression of PD-L1, a ligand of PD-1, on tumor cells and/or inflammatory cells such as T cells and monocytes/macrophages. 4 Binding of PD-1 to PD-L1 inhibits T-cell activation, allowing tumor cells to bypass immune surveillance. Thus, the blockade of PD-1/PD-L1 that reactivates tumor immunity has offered new hopes to cancer immunotherapy. 5, 6 In the field of lung cancer, anti-PD-1/ PD-L1 antibodies showed clinical response and improvement of prognosis in advanced non-small-cell lung cancer (NSCLC) in clinical trials, [7] [8] [9] [10] and subsequently two anti-PD-1 agents, nivolumab and pembolizumab, were approved by the U.S. Food and Drug Administration for treatment of advanced NSCLC.
Importantly, the response to anti-PD-1/PD-L1 agents in NSCLC, in particular in ADC, is often associated with PD-L1 expression on tumor cells (and/or immune cells) that is detectable by immunohistochemistry (IHC), suggesting that PD-L1 expression detected by IHC may serve as a predictive biomarker for anti-PD-1/PD-L1 therapies. [7] [8] [9] [10] However, it has been shown that PD-L1 expression can be heterogeneous within a primary NSCLC, 11, 12 raising a question as to whether PD-L1 expression is a sufficient predictive biomarker, whereas the concordance of PD-L1 expression between the primary and metastatic sites such as mediastinal lymph nodes has not been well studied in ADC. Furthermore, there have been conflicting results as to whether PD-L1 expression detected by IHC serves as a prognostic marker in resected ADC, 13 and little is known about the role of PD-L1 expression in predicting response to standard chemotherapy. Thus, the aims of this study were twofold: (1) to compare the expression between the primary tumor and metastatic lymph nodes in surgically resected stage II and III ADC and (2) to evaluate and correlate PD-L1 expression with clinicopathologic features and prognosis of patients, including those treated with platinum-based adjuvant therapy.
Materials and Methods

Patients
This study was approved by the institutional review board of Massachusetts General Hospital. The lung cancer database of the surgery department at our institution was queried for stage II or III lung ADCs resected with curative intent between 2002 and 2010, which resulted in the identification of 224 patients. Of those, 115 were excluded from the study for the following reasons: neoadjuvant therapy in 42 (19%), mixed histologic type in 22 (9.8%), multiple primaries in nine (4.0%), positive surgical margin in two (0.9%), active advanced bladder cancer in one (0.4%), and no tumor blocks available in 39 (17%). The remaining 109 patients formed our study cohort. Demographic information and information from imaging studies, surgical procedures, and postoperative follow-up, including information on adjuvant chemotherapies, was retrieved from the patient medical records. Recurrence-free survival (RFS) was measured from the time of resection to the development of clinical/radiographic recurrence. Patients who were alive without documented clinical/radiographic disease recurrence were censored on the date of last follow-up.
Pathologic Examination
All primary tumor slides (median five slides, range one to seven) were reviewed by three of the authors (H.U., E.B., and M.M.K), who were blinded to the clinical information. The size of the tumor, tumor (pT) and nodal (pN) stages, histologic pattern, nuclear grade of the tumor cells, presence or absence of pleural invasion, lymphatic invasion, vascular invasion, and necrosis were recorded. The histologic pattern of the tumor was classified in accordance with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) multidisciplinary classifications, which consist of ADC in situ, minimally invasive ADC, lepidic predominant ADC, papillary predominant ADC, acinar predominant ADC, micropapillary predominant ADC, solid predominant ADC, and ADC variants. 14 The final stage of tumor was determined in accordance with the American Joint Committee on Cancer (AJCC), seventh edition. 15 Nuclear grade was semiquantitatively assessed on a scale of 1 to 3. In addition, the presence or absence of tumor island 16 and tumor spread through air spaces 17 0 -diaminobenzidine was applied to the sections for 10 minutes. Subsequently, the sections were counterstained with hematoxylin for 5 minutes.
The IHC staining was independently assessed by three observers (H. U., E. B. and M. M.-K.), who were blinded to the clinical and pathologic data. When a discrepancy between the three observers was noted, the slides were reviewed under a multi-head microscope and discussed to determine the final score. PD-L1 expression was evaluated in both the primary tumor and nodal metastasis, and the percentage of tumor cells with positive membranous staining of any intensity was recorded and dichotomized as negative or positive for cutoffs of 1%, 5%, and 50% in accordance with previously published studies and clinical trials ( Fig. 1A and B and Supplementary Fig. 1 ).
7-10 CD8-positive T cells infiltrating the primary tumor were semiquantitatively assessed with a four-tiered (0-3) grading system, individually on the tumor cells, within the tumor stroma, and at the invading border, if it was clearly identified ( Fig. 1C and D). Each grade of the tumor cells was defined on the basis of the fraction of tumor cells on top of which positive T cells were present: 0, none or rare; 1, less than 5%; 2, at least 5% but less than 25%; and 3, at least 25%. CD8-positive T cells in the tumor stroma were graded on the basis of the fraction of positive cells in the stroma: 0, less than 1%; 1, at least 1% but less than 10%; 2, at least 10% but less than 50%; and 3, at least 50%. CD8-positive T cells at the tumor border were evaluated in the stroma by using the same grading system as for CD8-positive T cells in the tumor stroma.
Statistical Analysis
Statistical analysis was performed by a biostatistician (A.M.), an oncologist (A.G.), and H.U. with SAS version 9.4 and JMP Pro version 11 software (SAS Institute, Inc., Cary, NC) and SPSS version 23 software (IBM Corp., Armonk, NY). Fisher's exact test, the chi-square test, and Wilcoxon's signed rank test were used for univariate analysis to determine clinicopathologic parameters' impact on PD-L1 expression. Multivariate analysis was performed with a binary logistic regression model to evaluate for independent predictors of PD-L1 expression after adjustment for potential confounders. PD-L1 expression of the primary tumor and that of lymph node metastasis were compared by chi-square or Fisher's exact test, as appropriate. Survival analysis for RFS was performed by using the Kaplan-Meier estimator and the log-rank test. Multivariate survival analysis was performed with a Cox proportional hazards regression model to adjust for potential confounders for the association between clinicopathologic characteristics and RFS. All p values were two sided and considered statically significant when less than 0.05.
Results
Correlation of PD-L1 Expression in the Primary Tumor with Clinicopathologic Features
The study cohort (n ¼ 109) had a mean age of 66 years (range 42-83), and 56% were female. PD-L1 expression was present in 56 (51%), 43 (39%), and 19 (17%) cases using cutoffs of at least 1%, at least 5%, and at least 50%, respectively. PD-L1 expression with a 1% cutoff was associated with the following: higher N stage (p ¼ 0.004); solid dominant histologic pattern according to the IASLC/ATS/ERS classification (p < 0.001); higher nuclear grade (p ¼ 0.014); and presence of tumor island (p ¼ 0.037), necrosis (p ¼ 0.017), and vascular invasion (p ¼ 0.049). In contrast, age, sex, and smoking history (10 pack-years or more) had no bearing on PD-L1 expression (Supplementary Table 1) .
As for the tumor-infiltrating lymphocytes (TILs), abundant (grade 2-3) CD8-positive T cells on the tumor cells were present in 29 tumors (27%). Of those, 25 (86%) demonstrated both increased CD8-positive T cells and PD-L1 expression in tumor cells (p < 0.001). Similarly, prominent CD8-positive T cells in the stroma were present in 46 cases (42%), of which 37 (80%) showed concurrent PD-L1 expression (p < 0.001). A welldemarcated tumor border was identified in 84 of 109 cases (77%). Of those, 36 (43%) exhibited prominent CD8-positive T-cell infiltration at the tumor border and 27 of 36 (75%) showed concurrent PD-L1 expression (p ¼ 0.003). Thus, PD-L1 expression on the tumor cells was significantly associated with abundant CD8-positive T cells of all three compartments, and the CD8-positive T-cell infiltration on the tumor cells best correlated with PD-L1 expression. PD-L1 expression with cutoffs of 5% and 50% showed clinicopathologic characteristics similar to those with a 1% cutoff (Supplementary  Tables 2 and 3) .
Logistic regression analysis was constructed by including pathologic T stage, N stage, IASLC/ATS/ERS histologic pattern, nuclear grade, necrosis, vascular invasion, and CD8-positive T cells on the tumor cells, and it revealed that only prominent intratumoral CD8-positive T cells (p < 0.001) and N stage (p ¼ 0.013) remained significant predictors of PD-L1 expression with a 1% cutoff (Table 1) . Similarly, prominent intratumoral CD8-positive T cells (p < 0.001) and high-grade nuclei (p ¼ 0.001) were significant predictors of PD-L1 expression with a 5% cutoff (Supplementary Table 4 ), whereas only prominent intratumoral CD8-positive T cells were a nonsignificant predictor of PD-L1 expression with a 50% cutoff (p ¼ 0.076) (Supplementary Table 5 ).
PD-L1 Expression in Lymph Node Metastases
Of 37 pN1 cases, 39 pN2 cases, and one pN3 case, the highest levels of lymph nodes with a decent amount of tumor cells (100 or more) were available for analysis in 33 cases, 32 cases, and one case, respectively. PD-L1 expression in N1 and N2 lymph nodes correlated significantly with that in the primary tumor (p < 0.0001 and p ¼ 0.0036, respectively) (Supplementary Fig. 2A and B). In the sole case with a positive N3 lymph node, both the main tumor and N3 lymph node exhibited PD-L1 expression in 40% of the tumor cells. Of 39 pN2 cases, both the positive N1 and N2 lymph nodes were available for analysis in 23 and showed a significant correlation in PD-L1 expression (Supplementary Fig. 2C ). When various cutoffs were used to compare PD-L1 expression between the primary tumor and N1 and N2 lymph nodes, the expression was discrepant between the primary tumor and N1 lymph node in 15% to 18% of cases (Table 2) , between the primary tumor and N2 lymph node in 9.4% to 38% of cases (Table 3) , and between N1 and N2 lymph nodes in 0% to 17% of cases (Supplementary Table 6 ). Although the expression was similar in most of the combinations with various cutoffs, PD-L1 expression with a 1% cutoff in N2 lymph nodes was not correlated with that of the primary tumor ( Table 3) .
To identify the possible mechanisms of the discrepant expressions, we reviewed and compared the predominant histologic pattern in the section used for PD-L1 IHC between the metastatic lymph node and the primary tumor (Supplementary Table 7 ). In this analysis, we defined a significant difference in PD-L1 expression between the primary and N1 or N2 lesions and between N1 and N2 lesions as the expression in less than 1% versus in at least 5% of the tumor cells, that in less than 5% versus in at least 10% of the tumor cells, or that in less than 25% versus in at least 50% of the tumor cells. Of 11 cases in which the predominant histologic pattern was different between the primary and N1 lesions, seven (64%) showed a significant difference in PD-L1 expression between the two lesions ( Supplementary Fig. 3 ), whereas only one of 22 cases (4.5%) with the same predominant pattern in the two lesions showed a significant difference in PD-L1 expression (p ¼ 0.013). In addition, there was a nonsignificant association between the concordance of histologic patterns and that of PD-L1 expression in the primary tumor versus in N2 metastasis (p ¼ 0.113) and in N1 versus in N2 metastases (p ¼ 0.072).
PD-L1 Expression and RFS
Of the 109 patients, 60 had received platinum-based adjuvant therapy (32 received cisplatin doublets, 25 received carboplatin doublets, and no details were available in three cases) and were followed up at our institution.
In the entire study cohort, 5-year RFS was similar between the PD-L1-positive and PD-L1-negative groups with all cutoffs (57% versus 45%, log-rank p ¼ 0.283 for the 1% cutoff; 55% versus 48%, log-rank p ¼ 0.373 for the 5% cutoff; and 55% versus 50%, log-rank p ¼ 0.888 for the 50% cutoff) ( Fig. 2A and Supplementary Figs. 4A  and 5A ). Conversely, in the subset treated with platinumbased adjuvant therapy, patients with lung ADC exhibiting PD-L1 expression with 1% and 5% cutoffs, but not with a 50% cutoff, had significantly longer 5-year RFS (56% versus 30%, log-rank p ¼ 0.026 for the 1% cutoff; 57% versus 36%, log-rank p ¼ 0.040 for the 5% cutoff; and 57% versus 42%, log-rank p ¼ 0.3777 for the 50% cutoff) compared with those with negative PD-L1 expression ( Fig. 2B and Supplementary Figs. 4B and 5B). However, these associations of PD-L1 and longer RFS did not remain significant by multivariate analysis using the Cox regression mode, possibly owing to the small sample size. In this multivariate model, PD-L1 expression, AJCC stage, IASLC/ATS/ERS histologic pattern, lymphatic invasion, and intratumoral CD8-positive TILs were included as variables, and the results showed that only higher AJCC stage was a significant predictor of shorter RFS (hazard ratio ¼ 1.743, 95% confidence interval: 1.121-2.710, p ¼ 0.014 for all cutoffs [1%, 5%, and 50%]) Interestingly, PD-L1 expression with a 1% cutoff was a significant predictor of shorter RFS in the multivariate model (hazard ratio ¼ 1.919, 95% confidence interval: 1.064-3.461, p ¼ 0.030).
Discussion
PD-L1 expression on tumor cells has been shown to provide a mechanism of immune evasion through downregulation of active immune response, 5, 6 and blockade of the PD-1/PD-L1 axis is reportedly effective in various tumors, including NSCLC. [7] [8] [9] [10] In this study, we showed that PD-L1 expression in the primary tumor was associated with a higher rate of nodal metastasis, as well as with a few adverse pathologic features in stage II and III ADC, whereas abundant CD8-positive TILs (± N stage or high-grade nuclei) were the only predictor of PD-L1 expression by multivariate analysis. Kim et al. recently reported the association of PD-L1 expression and infiltration of CD8-positive T cells in their squamous cell carcinoma cohort, which is consistent with our results. 18 Similarly, Tumeh et al. have shown in their melanoma cohort that abundant CD8-positive T cells in the tumor and at the invasive border correlated with PD-L1 expression and clinical response of anti-PD-1 therapy. 19 The study also suggested that interferons produced by CD8-positive T cells affect PD-L1 expression on the tumor cells. Furthermore, several experimental studies have shown that PD-L1 suppresses active immune response to the tumor by inhibiting effector functions of T cells [20] [21] [22] [23] along with other mechanisms inducing apoptosis and exhaustion of effector T cells and recruitment of regulatory T cells. 4, 24 These results indicate the presence of acquired immune resistance and possible response to anti-PD-1/PD-L1 agents in tumors with abundant CD8-positive TILs.
To evaluate the heterogeneity of PD-L1 expression, we compared PD-L1 expression between the primary tumor and lymph node metastases that were obtained at the same time. Whereas the PD-L1 expression status with various cutoffs was concordant between the primary tumor and N1 or N2 lymph nodes in most cases, up to 38% of the cases showed discrepant PD-L1 expression between the primary tumor and the corresponding metastatic lymph node, raising the possibility of intertumoral heterogeneity of PD-L1 expression. Kim et al. also reported a similarly discrepant rate (30%) of PD-L1 expression in resected squamous cell carcinomas with nodal metastasis. 18 Similarly in melanoma, the PD-L1 expression status was concordant between the primary tumor and lymph node metastasis in 74% of the examined cases, whereas the concordant rate dropped to 52% when PD-L1 expression was compared between the primary tumor and distant metastasis. 25 Furthermore, the recent studies have reported discordance rates of 25% to 48% between PD-L1 expression detected in small specimens including the tissue microarray core and that in the corresponding whole section of NSCLC. The results are suggestive of intratumoral heterogeneity of PD-L1 expression. 11, 12 We further evaluated the morphology of tumor deposits in the lymph nodes. Comparing the predominant histologic pattern and PD-L1 expression between the primary and nodal metastasis in our cohort revealed that most cases with discrepant PD-L1 expression were attributed to the difference in the predominant histologic pattern of tumor between the primary and lymph node and between N1 and N2 lymph nodes. The results indicate spatial heterogeneity of histologic pattern as well as PD-L1 expression that may reflect spatial heterogeneity of tumor cell biology within the tumor and raise a concern about selecting the most appropriate tissue sample for assessment of PD-L1 expression that may determine the eligibility for treatment with anti-PD1/ PD-L1 agents. Several studies have correlated PD-L1 expression with patient outcomes in NSCLC, reporting conflicting results. 18, [26] [27] [28] [29] To our knowledge, however, there have been only a few studies on the role of PD-L1 expression in predicting response to platinum-based therapy. Sorensen et al. reported no significant association between PD-L1 expression and overall survival (OS) in an advanced lung ADC and squamous carcinoma cohort with the vast majority treated with carboplatin doublets. 30 The recent study by Tokito et al. also showed that PD-L1 expression had no bearing on progressionfree survival and OS, whereas high CD8-positive TIL density was a predictor of improved progression-free survival and OS in 74 patients with stage III NSCLC treated with concurrent platinum-based chemoradiation. 31 The study with 1070 patients with surgically resected NSCLC showed that PD-L1 expression was associated with shorter RFS and OS in the entire cohort, but its significance was weakened by postoperative therapy. 29 In the current study, PD-L1 expression with 1% and 5% cutoffs was associated with improved survival in a small subset of patients who had received platinum-based adjuvant therapy by univariate analysis, although the predictive value of PD-L1 did not remain by multivariate analysis. Conversely, in the entire cohort, whereas PD-1 expression had no bearing on RFS by univariate analysis, PD-L1 expression with a 1% cutoff was a significant predictor of shorter RFS by multivariate analysis. Thus, platinum-based adjuvant therapy may improve survival in patients with lung ADC exhibiting PD-L1 expression, which is consistent with the report by Sun et al. 29 Now, several lines of evidence suggest immunologic effects of platinum chemotherapeutics on the tumor microenvironment that enhance antitumor Tcell immunity owing in part to downregulation of the PD-1 pathway. 32 Thus, we hypothesize that the PD-L1 expression that is often seen in association with a cytotoxic T-cell microenvironment may serve as a biomarker predictive of response to platinum-based chemotherapy.
There were several limitations in our study. First, the study was retrospective and the cohort consisted of a relatively small number of patients treated in a single center. Many of the patients with stage IIIA disease at presentation were not included in the study because patients with stage IIIA NSCLC with bulky nodal metastasis, good performance status, and no comorbidity are usually treated with neoadjuvant therapy at our institution. Furthermore, no tumor blocks were available in a significant number of cases, in particular in those resected in 2006 or earlier. However, there was no difference in age, sex, smoking status, or AJCC stage between the study cohort and those excluded owing to the lack of available tumor blocks (data not shown). Nevertheless, the small cohort size might have hampered the prognostic assessment. Second, our cohort consisted of slightly more female patients than male patients, which is different from the reported male predominance in lung cancer. However, this slight female predominance was also seen in the entire group of patients with stage II and III lung ADC resected in the same period at our institution (data not shown). Thus, it does not appear to be attributed to selection bias due to the study design. Third, there is currently no accepted standard in PD-L1 testing, and a number of different antibodies, IHC protocols, and/or cutoffs for positivity have been applied 13 To account for this, we used a commercially available anti-PD-L1 antibody that has been independently validated. 18, [33] [34] [35] We also used three cutoffs that have been associated with beneficial response to a PD-1 inhibitor in clinical trials. [7] [8] [9] [10] Finally, molecular data were not available for most of our patients with stage II or III; thus, we could not correlate PD-L1 expression with molecular characteristics. There have been conflicting results as to whether PD-L1 expression is associated with certain molecular alterations such as EGFR mutations and anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements in ADC. 28, [36] [37] [38] We have recently shown that KRAS mutations and their clinicopathologic signatures are predictors of PD-L1 expression in a cohort consisting mostly of stage I ADC. 39 Nevertheless, further studies are warranted to identify molecular correlates of PD-L1 expression.
In summary, in our stage II and III ADC cohort, PD-L1 expression was associated with abundant CD8-positive TILs, supporting the presence of adaptive immune resistance. The discrepant PD-L1 expression status between the primary tumor and lymph node metastases (intertumoral heterogeneity) seen in the significant minority raises a concern as to which sample should be evaluated for PD-L1 IHC that may determine eligibility for treatment with anti-PD-1/PD-L1 agents. Although the evaluation was limited because of the small cohort size, PD-L1 expression in the primary tumor was associated with longer RFS after surgery and platinum-based adjuvant therapy, whereas PD-L1 expression had no bearing on RFS in the entire cohort.
